Is Olaparib a domestic drug or an imported original drug?
Olaparib is an imported original drug that is currently on the market in China and has been included in the medical insurance system. This drug, developed by AstraZeneca, is a PARP inhibitor drug and is mainly used to treat patients with ovarian cancer, breast cancer and other cancers with BRCA mutations. As an imported drug, Lynparza has gone through strict domestic drug approval procedures and has been widely used among patients. Patients can purchase the drug through hospital pharmacies or formal channels.
The domestic market price of Lynparza is approximately 4,000 to 5,000 yuan, and the specification is 150mg*56 tablets. Since it has been included in medical insurance, eligible patients can reimburse part of the expenses through medical insurance to reduce their financial burden. The specific medical insurance reimbursement ratio and policy will vary depending on the region, so patients need to consult the local hospital pharmacy for detailed medical insurance reimbursement conditions when purchasing.

For some patients with tight financial conditions, there are more affordable generic olaparib drugs on the overseas market. For example, the generic version of Lynparza produced in Bangladesh and Laos is 150mg*120 tablets, and the price is about 2,000 yuan, which is much lower than the price of the domestic original drug. Although the price of these generic drugs is lower, their ingredients are basically the same as the original drugs, and their efficacy and safety have been fully verified, so they have become the choice of some patients.
In general, olaparib mainly appears in the domestic market as an imported original drug, and has entered the medical insurance system, making it easier for more patients to use it. However, for patients who wish to save on treatment costs, overseas generic drugs offer a more economical option. Regardless of whether they choose original drugs or generic drugs, patients should fully consult under the guidance of a doctor before use to ensure drug safety and obtain the best therapeutic effect.
Reference materials:https://www.lynparza.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)